Furthermore, active MARK2 co-localizes with NFTs in AD brain, and MARK2 target sites on tau are elevated in transgenic mouse models of tauopathy, emphasizing the importance of MARK2 in this disease (Matenia and Mandelkow, 2009). This evidence concerns the gene MAPT and Alzheimer disease.